BioGaia AB (publ) (BIOG-B.ST)
- Previous Close
129.00 - Open
128.60 - Bid 133.30 x --
- Ask 133.20 x --
- Day's Range
128.40 - 133.90 - 52 Week Range
91.45 - 135.60 - Volume
178,144 - Avg. Volume
121,087 - Market Cap (intraday)
13.4B - Beta (5Y Monthly) --
- PE Ratio (TTM)
36.06 - EPS (TTM)
3.68 - Earnings Date Jul 7, 2024
- Forward Dividend & Yield 1.90 (1.47%)
- Ex-Dividend Date May 8, 2024
- 1y Target Est
159.00
BioGaia AB (publ), a healthcare company, provides probiotic products worldwide. The company operates through Pediatrics, Adult Health, and Other segments. The Pediatrics segment offers drops, oral rehydration solutions, and gut health tablets, as well as cultures that are used as an ingredient in infant formula. The Adult Health segment provides gut health tablets and oral health lozenges products, as well as cultures, which are used as an ingredient in a licensee's dairy product. The Other segment provides packaging solutions. It sells its products through distribution partners or through its own distribution channels. BioGaia AB (publ) was founded in 1990 and is based in Stockholm, Sweden.
www.biogaia.com210
Full Time Employees
December 31
Fiscal Year Ends
Sector
Recent News: BIOG-B.ST
Performance Overview: BIOG-B.ST
Trailing total returns as of 5/14/2024, which may include dividends or other distributions. Benchmark is .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: BIOG-B.ST
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: BIOG-B.ST
Valuation Measures
Market Cap
13.03B
Enterprise Value
11.44B
Trailing P/E
35.05
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
10.02
Price/Book (mrq)
6.01
Enterprise Value/Revenue
--
Enterprise Value/EBITDA
--
Financial Highlights
Profitability and Income Statement
Profit Margin
28.55%
Return on Assets (ttm)
11.35%
Return on Equity (ttm)
17.45%
Revenue (ttm)
1.3B
Net Income Avi to Common (ttm)
371.25M
Diluted EPS (ttm)
3.68
Balance Sheet and Cash Flow
Total Cash (mrq)
1.59B
Total Debt/Equity (mrq)
--
Levered Free Cash Flow (ttm)
176.75M
Research Analysis: BIOG-B.ST
Company Insights: BIOG-B.ST
BIOG-B.ST does not have Company Insights